BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19319534)

  • 1. Prolonged accumulation of high-dose methotrexate in a case with large liver cysts.
    Kawakami M; Omori H; Yamagami T; Soma T
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):619-22. PubMed ID: 19319534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
    Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
    Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
    Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
    Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late-onset delayed excretion of methotrexate.
    Pauley JL; Panetta JC; Schmidt J; Kornegay N; Relling MV; Pui CH
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):146-52. PubMed ID: 15148625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of malignant effusions on methotrexate disposition.
    Li J; Gwilt P
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):373-82. PubMed ID: 12439595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data.
    Fukuhara K; Ikawa K; Morikawa N; Kumagai K
    J Clin Pharm Ther; 2008 Dec; 33(6):677-84. PubMed ID: 19138246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate sequestration in an ovarian cyst.
    Jolin JA; Hutson PR; Schink JC
    Gynecol Oncol; 1999 Jan; 72(1):113-5. PubMed ID: 9889042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The need for a better definition of therapeutic indications of carboxypeptidase in delayed elimination of methotrexate].
    Blasco H; Silly S; Tournamille JF; Gyan E; Sénécal D; André V; Colombat P; Le Guellec C
    Therapie; 2008; 63(1):19-28. PubMed ID: 18387272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
    Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
    Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of Chai-ling-tang (Sairei-to) for methotrexate concentration degradation delay by methotrexate high-dose therapy].
    Utsuki S; Oka H; Suzuki S; Sato S; Osawa S; Koizumi H; Miyajima Y; Fujii K
    No Shinkei Geka; 2010 Feb; 38(2):133-7. PubMed ID: 20166525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fever as a risk factor causing delayed elimination of methotrexate in pediatric patients receiving high doses of cancer chemotherapy.
    Kagawa Y; Mukohara R; Hori H; Kawasaki H; Komada Y; Kojima M
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):34-8. PubMed ID: 15024606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow release properties and liver-targeting characteristics of methotrexate erythrocyte carriers.
    Yuan SH; Ge WH; Huo J; Wang XH
    Fundam Clin Pharmacol; 2009 Apr; 23(2):189-96. PubMed ID: 19298236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
    Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate for intraocular lymphoma.
    Batchelor TT; Kolak G; Ciordia R; Foster CS; Henson JW
    Clin Cancer Res; 2003 Feb; 9(2):711-5. PubMed ID: 12576439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy.
    Faltaos DW; Hulot JS; Urien S; Morel V; Kaloshi G; Fernandez C; Xuan kH; Leblond V; Lechat P
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):626-33. PubMed ID: 16528531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
    Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
    Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Delayed clearance of methotrexate in a patient with malignant lymphoma who developed renal failure].
    Wakita A; Komatsu H; Banno S; Nitta M; Nagai H; Uchida T; Murase T; Nakahara Y; Tanaka M
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):285-8. PubMed ID: 7857106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
    Cózar Olmo JA; Martínez Colmenero C; Peláez Pleguezuelos I; Leiva Gea I; López García AB; de la Cruz Moreno J
    An Pediatr (Barc); 2009 Sep; 71(3):230-4. PubMed ID: 19617010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.